ONTRUZANT Q Code: Q5112

Drug & Product Overview

HCPCS Descriptor Injection, trastuzumab-dttb, biosimilar, (ontruzant), 10 mg

HCPCS Added Date July 1, 2019

Manufacturer Organon

Route of Administration Intravenous

Generic Status Single-Source; Branded

Dosage Type Single-Dose, Multi-Dose

Dosage Form Injection, Powder, Lyophilized, For Solution | Kit

About ONTRUZANT

Ontruzant is a medication aligned to the HCPCS Q Code: Q5112 for billing, pricing, and reimbursement purposes in the United States. It is an Oncology drug administered via the intravenous route and manufactured by Organon.

According to CMS Drug Use Information: Trastuzumab is used to treat certain types of breast, stomach, or esophagus cancer. Trastuzumab belongs to a class of medications known as monoclonal antibodies. It works by slowing or stopping the growth of cancer cells. This monograph is about the following trastuzumab products: trastuzumab, trastuzumab-anns, trastuzumab-dkst, trastuzumab-dttb, trastuzumab-pkrb, trastuzumab-qyyp, trastuzumab-strf.

Disclaimer: This is a summary and does not contain all possible information about this product. For complete information about this product or your specific health needs, ask your healthcare professional.

NDC Code Information

Based on publicly available CMS files. The list of NDCs below is not exhaustive.

NDC Code	Drug	Manufacturer	Billing Units / Pkg	Package Size
78206-0147-01	Ontruzant	Organon LLC	15	150 MG
78206-0148-01	Ontruzant	Organon LLC	42	Kit

Login for the full NDC crosswalk View pricing, complete NDC-to-HCPCS alignments, and package details.

Login →

ONTRUZANT Pricing & Reimbursement

Q5112 Private Payer Reimbursement

$28.02 / HCPCS unit as of Jan 2026

National median reimbursement across major commercial payers.

Create an account on PayerPrice for more information →

Historical Graphing and Billing Calculator

per HCPCS unit

As of Q3 2026

Trastuzumab Biosimilar Information:

ONTRUZANT Approval Date: January 18, 2019

Product Name	HCPCS Code	Active Ingredient	BLA Type
Herceptin	J9355	Trastuzumab	351(a) Originator Product
Ogivri	Q5114	Trastuzumab	351(k) Biosimilar
Herzuma	Q5113	Trastuzumab	351(k) Biosimilar
Ontruzant	Q5112	Trastuzumab	351(k) Biosimilar
Trazimera	Q5116	Trastuzumab	351(k) Biosimilar
Kanjinti	Q5117	Trastuzumab	351(k) Biosimilar
Hercessi	Q5146	Trastuzumab	351(k) Biosimilar

ONTRUZANT Claims Performance

Claims from Jan 2026 – Aug 2026

Claim Denial Rate 10.43%

Avg. Days to File 8.8days

Avg. Days to Pay 19.6days

Real-world claims performance from FocalPoint, OnPoint Oncology's reimbursement analytics platform, with claims data accrued at the clearing house level.

Explore Q5112 claims analytics on FocalPoint →

ONTRUZANT CPT Administration Codes

CPT Code	Description
96413	Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug
96415	Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)

Not on the CMS JW / JZ list

CMS does not include Ontruzant (Q5112) on its list of HCPCS pertaining to single-dose containers. Per CMS guidelines, the JZ/JW wastage modifiers may not apply when billing Q5112. Wastage billing guide →

ONTRUZANT Medically Unlikely Edits (MUE)

The most billing units of Q5112 Medicare will pay for one patient in one day, as published by CMS. 1 unit = 10 mg.

Practitioner Office & Hospital Outpatient

120 units / day

= 1,200 mg per day

MAI 3 · Date of Service Edit: Clinical. Per-day limit based on clinical expectations; excess units are denied but may be appealed with documentation of medical necessity. See all MUE limits →

ONTRUZANT Clinical Information

Indications and drug classification.

Treated Diseases & Conditions

This list of indications is not exhaustive and may be subject to errors. The information on BuyandBill.com is intended for informational purposes only and should not be used for medical advice.

Breast Cancer Metastatic Breast Cancer Metastatic Gastric Cancer

Drug Class

HER2/Neu/cerbB2 Antagonists [MoA]HER2/neu Receptor Antagonist [EPC]

Frequently Asked Questions

Is there an available Ontruzant billing and coding guide?

Billing and coding information for ONTRUZANT can be found through Merck. Visit Here →

Are there any available Ontruzant patient assistance programs?

ONTRUZANT patient assistance information can be found through Organon. Visit Here →

Where can I find Ontruzant prescribing information?

ONTRUZANT prescribing information can be found at the link below: Visit Here →

Where can I find Ontruzant side effect information?

Our team has not yet identified a source of side effects information for ONTRUZANT. Please check back in a few weeks.

Does billing ONTRUZANT require JZ/JW wastage modifiers?

CMS does not include ONTRUZANT (Q5112) on its list of HCPCS pertaining to single-dose containers. Per CMS guidelines, the JZ/JW wastage modifiers may not apply when billing Q5112. For more information, visit the link below.

About BuyandBill.com:

The BuyandBill.com team is dedicated to delivering high-quality coding and billing information for office-administered drugs. We continuously research HCPCS-coded medications to expand our resources and ensure data accuracy. Manufacturers: click here to sponsor your medication, and we will ensure the most accurate and detailed information is displayed.